Summary Spheroids of a small-cell lung cancer (SCLC) cell line POC were used to evaluate the uptake and penetration of two antibodies recognising different SCLC antigens. Spheroids approximately 300-400 gm in diameter were incubated with 1 jig ml-"25I-labelled NY.3DI 1, an antibody which reacts with the cluster I group antigen (neural cell adhesion molecule; NCAM) and ['25I]SWAI 1, which binds to the cluster w4 antigen. The rate of uptake of both antibodies was similar; an initially rapid phase was seen during the first 8 h and maximum uptake occurred by 24 h. This increased to about 100 txm after 4 h incubation with I or 100 fig ml-' SWAI 1. The results with I lg mlh' NY.3D1 were similar, but in the presence of 100 jg ml-' NY.3DI I penetration into the spheroid was deep and diffuse. These results demonstrate a major concentration-dependent difference in the uptake and penetration of cluster I and cluster w4 antibodies in this spheroid model and they have implications for the selection of antibodies for targeted therapy of SCLC.
group antigen (neural cell adhesion molecule; NCAM) and ['25I]SWAI 1, which binds to the cluster w4 antigen. The rate of uptake of both antibodies was similar; an initially rapid phase was seen during the first 8 h and maximum uptake occurred by 24 h. The mean uptake per spheroid at 24 h was 0.97 ng for [251I]NY.3D1 I and 0.45 ng for [125I]SWA1 1. An objective measurement of antibody penetration into spheroids was developed using a computerised image analysis of immunostained sections of spheroids. The concentration of antibody and incubation times were varied. Both antibodies penetrated the spheroids to a depth of 50 ILm after 30 min.
This increased to about 100 txm after 4 h incubation with I or 100 fig ml-' SWAI 1. The results with I lg mlh' NY.3D1 were similar, but in the presence of 100 jg ml-' NY.3DI I penetration into the spheroid was deep and diffuse. These results demonstrate a major concentration-dependent difference in the uptake and penetration of cluster I and cluster w4 antibodies in this spheroid model and they have implications for the selection of antibodies for targeted therapy of SCLC.
Successful therapy with antibody conjugates is most likely to be achieved in tumours in which the burden of cells is low and tumour foci are small. Studies in animals with human tumour xenografts have demonstrated that the most favourable anti-tumour antibody uptake ratio is seen in small tumours (Rogers et al., 1986; Pedley et al., 1987) , and this probably accounts for the good results of radioimmunotherapy in these animals (Cheung et al., 1986; Buchegger et al., 1989; Smith et al., 1991) . In man radiolabelled antibodies have usually been given to treat large tumours, and although responses occur they are rarely sustained. It is likely that the best results of radioimmunotherapy in man will occur when treatment is given as an adjuvant to eradicate persistent micrometastases.
Small-cell lung cancer (SCLC) is a tumour ideally suited to adjuvant antibody-targeted therapy as about half the patients treated with current chemotherapy and radiation protocols enter a complete remission. However, subclinical disease remains as more than 95% of these patients eventually die of their disease (Souhami & Law, 1990) . Antibody-targeted radiotherapy could be given to patients in complete remission as at this time individual tumour foci may contain about 109 cells, i.e. 1 cm3 or less. The success of this approach will depend on delivering sufficient antibody to residual tumour deposits and on choosing a radiopharmaceutical with appropriate characteristics for the size of the tumour (Gaze et al., 1992) .
There are many antibodies that react with SCLC antigens and that could be considered as suitable agents for targeted therapy. Several of these have been grouped into clusters defined by two international workshops on the basis of a common pattern of reactivity (Souhami et al., , 1991 . Radiolabelled antibodies against clusters 1 and w4 have been shown to localise SCLC growing as a xenograft in 'nude mice' (Yoneda et al., 1988; Smith et al., 1989; Wilson et al., 1990; Boerman et al., 1991) (Sutherland & Durand, 1984) and they have been used as a model to compare the microdistribution of different anti-tumour antibodies (Sutherland et al., 1987) and to evaluate targeted radiotherapy (Gaze et al., 1992) .
We have used a human SCLC spheroid model to compare the behaviour of two antibodies that are potential vehicles for antibody-directed radiotherapy of SCLC. One antibody is directed against the cluster 1 antigen, the neural cell adhesion molecule (NCAM) (Patel et al., 1989 ) expressed on SCLC, and the other is against the cluster w4 antigen (Smith et al., 1989) , which has recently been shown to be identical to a leucocyte activation antigen CD24 (Jackson et al., 1992) .
Materials and methods
Cells and spheroid culture The POC cell line obtained from P. Twentyman (MRC, Cambridge, UK) and the UCH10 cell line (Kardamakis et al., 1988) (Smith et al., 1989) . Antibodies were purified from tissue culture supernatant by protein A-Sepharose chromatography. Two anti-NCAMs, ERIC-1, an IgGI (Bourne et al., 1991) , and an IgG2a antibody (both supplied by J. Kemshead, ICRF, Frenchay Hospital, Bristol, UK) were used as positive controls. A locally produced IgGI antibody, QS4120, an anti-human CD4 (P. Beverley, personal communication) was used as a negative control antibody.
Antibodies were radiolabelled with 1251I by the iodogen method with a specific activity of approximately 1 mCi mg-'. Antibody immunoreactivity was determined using a cellbinding assay (Trucco & de Petris, 1981) . A fixed amount of antibody (approximately 16,500 c.p.m.) was added to a range of UCH1O cells (107 to 6.25 x 106) for 2 h at 4°C. After washing bound counts were measured and the number of unbound counts was plotted (y-axis) against the reciprocal cell number. The difference between input and unbound counts at the intercept on the y-axis gives the theoretical immunoreactive fraction at an infinite excess of antigen. Antibody affinity (K) and binding sites (n) were determined as described by Trucco and de Petris (1981 
Results
Uptake of cluster I and w4 antibodies in SCLC spheroids The antibody NY.3D1 1 binds to human NCAM expressed on the surface of cells. In the experiment shown in Figure 1 the antibody was incubated with D243, a mouse fibroblast cell line that had been transfected with cDNA encoding the 140 kDa isoform of human skeletal muscle NCAM. NCAM is expressed on the surface of these cells and the fluorescence histogram (Figure la and b) shows binding of NY.3D1 1 to D243 but not to the parent mouse fibroblast line. Both NY.3D11 and SWAl1 bound to the two SCLC lines, POC and UCH1O cells ( Figure Ic and d) .
POC spheroids with a diameter of 300-400 1m contained about 104 cells. The proporton of dividing cells was not determined, but visible signs of necrosis were not apparent until the diameter exceeded 500pLm. The binding affinity of NY.3D1I1 and SWA 11 for UCH1O cells is shown in Figure 2 . The immunoreactive fraction determined by the method of Trucco and de Petris (1981) It showed that differences in the penetration of the two antibodies into spheroids were not significantly different in the presence of 1 tLg ml-' antibody but were strikingly different in the presence of 100 sg ml-' (Figure 4) . The distribution of NY.3D1 across the spheroid section was fairly uniform, but deposition of SWA 11 was seen mainly in a rim extending no more than 100 gm from the surface of the spheroid. These differences are clearly seen in the photomicrographs shown in Figure 5 . Following 30 min incubation NY.3Dl and SWAl had penetrated to a depth of about 3-4 cell layers (50 gtm) from the surface of the spheroid. The intensity of staining of SWA 11 at 4 h is greater than NY.3D 1, but the latter has penetrated more deeply and diffusely into the spheroid. The antibodies appeared to be localised around the surface of the cells. No uptake of the control antibody, QS4120, was seen at 4 h. Direct incubation of tissue sections with antibody showed a homogeneous distribution of cluster 1 and cluster w4 antigens (Figure 4) . Antigen was not detected in areas of central necrosis seen in some spheroids larger than 400 .tm in diameter. A high intensity of staining was seen at the rim of the spheroids stained for antigen. This peak is unlikely to be an artefact due to high concentrations of antibody in the surrounding medium. It could have been due to tissue shrinkage during penetration of the spheroid or to a true increase in the concentration of antigen at the surface of the spheroid.
Discussion
The purpose of this study was to compare the uptake and penetration of two distinct antibodies to SCLC antigens in antigens and control antibody (I jig ml-') in POC spheroids.
Mean uptake and standard deviation are shown. 1991) and cluster 1 and w4 antigens are commonly found in tumours of patients (Souhami et al., 1991) . The patterns of uptake of NY.3DII and SWAl1 in POC spheroids were similar. A rapid phase of accumulation during the first 8 h was followed by only a small increase in uptake over the next 16 h. The decrease in uptake of radiolabelled antibody after 8 h was not due to exhaustion of the supply of antibody as only a small fraction of antibody in the incubation medium bound to spheroids. The results are similar to those reported in studies of human melanoma, colon and ovarian carcinoma spheroids (Kwok et al., 1988; Langmuir et al., 1990; Bardies et al., 1992) Distance (,jrm) NCAM, ERIC-1, which suggests that the different behaviour was due to interaction of the antibody with its antigen. It is possible that the 72a subclass of SWA 11 behaved differently from the y1 subclass of NY.3D 1. However, when we used an IgG2a cluster 1 antibody we did not see any difference in penetration into the spheroid compared with the IgGl cluster I antibody (data not shown). Antibody uptake in tumour spheroid models can be improved by greatly increasing the concentration of the incubating antibody (Kwok et al., 1988; Langmuir et al., 1990; Bardies et al., 1992) . Studies were performed with 1 gig ml-1 antibody, as this is a concentration that can be realistically maintained in the blood of patients for several hours. Accumulation of [251I]NY.3D1 1 at this dose was greater than that of ['251I]SWA 11, but the difference was not such that any change in the depth of penetration of the two antibodies was detectable by immunohistochemistry. A major difference in the depth of penetration of the two antibodies was seen only with 100 Lg ml-' incubating antibody. While it is possible to achieve high peak levels of antibody in blood, it is not clear whether high levels can be sustained for a sufficient time to alter the depth of penetration of an antibody.
Most previous studies with radiolabelled antibodies have shown that much of the radioactivity resides on the surface or outer layers of spheroids expressing membrane antigens (Sutherland et al., 1987; Pervez et al., 1989; Langmuir et al., 1990; Chen et al., 1991) . The inability of antibodies to penetrate deeply into a tumour mass reduces the efficacy of radioimmunoconjugate therapy (Bardies et al., 1992) . Much work has been devoted to studying factors that affect the uptake and penetration of anti-tumour antibodies in tumours, as they have an important bearing on the success of antibody-targeted therapy. The size of the tumour (Pedley et al., 1987) , local interstitial pressures (Jain, 1988) and size of the immunoglobulin molecule (Sutherland et al., 1987) are all likely to be influential factors. Furthermore, antigens may not be homogeneously distributed on the surface membrane.
Distance (,urm) 1 fig ml' ). The difference in penetration of the antibodies was not related to the distribution of cluster 1 and w4 antigens, which was shown by immunohistochemistry to be fairly uniform and on the surface membrane of cells. However, SWAl1 is internalised by cells (Derbyshire et al., 1992) , and this may retard its penetration through spheroids. There is no evidence that the cluster 1 antibodies are internalised (R.L. Souhami, unpublished observations). Alternatively, differences in the depth of penetration of antibodies into spheroids could be related to antibody affinity. It has been suggested that the interaction of high-affinity antibodies at the surface of a tumour prevents its penetration (Fujimori et al., 1989; van Osdol et al., 1991) . We were unable to measure reproducibly the affinity of the antibodies on POC cells, as it was difficult to prepare a single-cell suspension that was not heavily contaminated by dead cells which accumulated radiolabelled antibody non-specifically. There was little difference in the affinity of SWAII and NY.3D11 on UCH1O cells which grow as a cell suspension. It is unlikely that the affinity of these antibodies for their antigen would be significantly different on POC cells and we therefore believe that the differences in the penetration of these antibodies into spheroids are unlikely to be related to their affinity for the antigen. However, there were approximately five times as many antigen binding sites for SWA1 1 on UCH10 compared with NY.3D11. Cell-binding studies by FACS analysis showed that the mean fluorescence from SWAI1 binding to UCH10 and POC was greater than from NY.3DII ( Figure  1 ), suggesting that there were more antigen binding sites for SWAl1 on both cell lines. If the antigen densities on POC and UCH10 are similar then one could envisage that a high density of antigen might lead to a deposition of SWA 11 near the surface of the spheroid, forming a barrier which might prevent further penetration of antibody. The lower density of cluster 1 antigen might permit a more diffuse penetration of antibody through the spheroid.
Differences in the behaviour of antibodies in the tumour environment are difficult to measure in patients, and in particular in SCLC, in which the aim of treatment is to eradicate small-volume residual disease. The spheroid model of SCLC has been shown to be a useful method of studying differences in the pattern of uptake of cluster 1 and w4 antibodies. The results may have implications for the choice of antibody and conjugate most likely to be effective in therapy of SCLC. However, selection of the most suitable radiopharmaceutical will also depend upon the results of clinical studies that examine biodistribution and tumour localisation of these two antibodies. We have recently shown that radiolabelled SWAI1 localises in tumours, but it also accumulates in areas rich in granulocytes, making it unsuitable for targeted therapy of SCLC (Ledermann et al., 1993) . A study of the biodistribution of radiolabelled NY.3DIl in patients is to start shortly.
